[Sudden death and chronic cardiac insufficiency].
Sudden death accounts for about 35% of the mortality of cardiac failure and its incidence does not decrease with the use of angiotensin converting enzyme inhibitors. Non-sustained ventricular tachycardia on Holter monitoring, late ventricular potentials and tachycardia induced by programmed ventricular stimulation have no formal predictive value of sudden death, underlining the varied character of the mechanisms underlying sudden death during cardiac failure. Sustained ventricular tachycardia degenerating to ventricular fibrillation is only one of the rhythmic factors implicated together with inaugural ventricular fibrillation, bradyarrhythmias and electromechanical dissociation. The underlying cardiac disease plays a role in the initiation of the fatal arrhythmia. In coronary artery disease, recurrent acute ischaemia is the principal trigger factor in patients who often have triple vessel disease. This explains the fact that classic markers of arrhythmia in the post-infarction period, which are only the reflection of the arrhythmogenic substrate of ventricular tachycardia, usually due to reentry around the fibrous scar of the infarct, are not valid in patients with progressive ischaemic cardiomyopathy. The most effective antiarrhythmic treatment in this type of patient is the prevention of ischaemia, when possible. In primary dilated cardiomyopathy, the mechanism underlying sudden death could be different at each stage. In NYHA Stages I and II, ventricular tachyarrhythmias could play a major part in unexpected sudden death in patients whose stable haemodynamic status suggested a more prolonged survival. The value of an implantable defibrillator would seem to be proved in this group of patients, at least in secondary prevention. In Stages III and IV, ventricular arrhythmias only indicate the degree of ventricular dysfunction and sudden death may follow bradyarrhythmias and electromechanical dissociation due to the precarious haemodynamic status.
Galinier
M
M
Service de cardiologie clinique et expérimentale, CHU Rangueil, Toulouse.
Boveda
S
S
Alhabaj
S
S
Armengaud
J
J
Cabrol
P
P
Dongay
B
B
Massabuau
P
P
Fauvel
J M
JM
Bounhoure
J P
JP
D002303:Cardiac Output, Low / Q000150:complications / Q000401:mortality* / Q000503:physiopathology / Q000628:therapy; D002908:Chronic Disease; D016757:Death, Sudden, Cardiac / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D005602:France / Q000453:epidemiology; D006801:Humans; D007049:Iatrogenic Disease; D015994:Incidence; D011237:Predictive Value of Tests; D012307:Risk Factors